Envestnet Asset Management Inc. Boosts Stake in CVS Health Corporation $CVS

Key Points

• Envestnet Asset Management increased its CVS Health stake by 80.9% in the second quarter, adding 1.55 million shares to reach approximately 3.48 million shares worth $359.5 million. Institutional investors collectively own 80.66% of CVS.
• CVS reported stronger-than-expected quarterly results, with adjusted earnings of $2.58 per share and revenue of $106.1 billion, up 7.3% year over year. The company maintained fiscal 2026 earnings guidance of $7.90–$8.10 per share.
• Analysts remain broadly positive, with 22 Buy ratings and one Hold rating, an average “Moderate Buy” rating, and a consensus price target of $107.24 versus the reported share price of $85.84. CVS also pays a quarterly dividend of $0.665, yielding about 3.1% annually.

Envestnet Asset Management Inc. lifted its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 80.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,475,264 shares of the pharmacy operator's stock after purchasing an additional 1,554,354 shares during the quarter. Envestnet Asset Management Inc. owned about 0.27% of CVS Health worth $359,516,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Kilter Group LLC purchased a new position in shares of CVS Health in the second quarter valued at approximately $27,000. Sankala Group LLC purchased a new stake in CVS Health during the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC lifted its holdings in CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after buying an additional 300 shares in the last quarter. Beaird Harris Wealth Management LLC boosted its position in CVS Health by 201.0% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator's stock valued at $30,000 after buying an additional 195 shares during the period. Finally, J.Safra Asset Management Corp acquired a new position in shares of CVS Health in the second quarter worth $30,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Down 1.5%

NYSE:CVS opened at $85.84 on Thursday. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The stock has a market cap of $109.78 billion, a P/E ratio of 22.71, a P/E/G ratio of 0.85 and a beta of 0.59. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a 50-day simple moving average of $97.63 and a 200-day simple moving average of $91.51.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. During the same quarter last year, the company earned $1.81 earnings per share. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.1%. The ex-dividend date was Thursday, July 23rd. CVS Health's dividend payout ratio is currently 70.37%.

Analyst Ratings Changes

CVS has been the topic of several analyst reports. Robert W. Baird set a $107.00 price objective on CVS Health in a research note on Thursday, August 6th. Royal Bank Of Canada boosted their target price on CVS Health from $107.00 to $113.00 and gave the stock an "outperform" rating in a research note on Thursday, July 9th. Wall Street Zen raised CVS Health from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Argus boosted their price objective on CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. Finally, Barclays upped their target price on shares of CVS Health from $106.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.24.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Polaris Capital Management highlighted CVS’s strengthened second-quarter performance in its global-equity investor letter. CVS’s recent results included better-than-expected earnings and revenue growth, supporting the long-term recovery and growth case. Here’s What Strengthened CVS Health in Q2
• Positive Sentiment: Recent Zacks commentary characterized CVS as a potentially attractive long-term growth stock, with valuation and its broad healthcare platform offering support for investors willing to look beyond near-term volatility. Why CVS Health Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: CVS reminded Tennessee residents that MMR vaccines are available at its pharmacies and MinuteClinics following nine reported measles cases. The announcement may support pharmacy traffic and public-health engagement, but it is unlikely to materially affect earnings. CVS Health Reminds Residents Vaccines Are Available
• Neutral Sentiment: Analyst commentary comparing CVS with Cardinal Health focused on valuation, performance and price targets rather than a new company-specific catalyst, providing context but limited immediate trading impact. CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now?
• Neutral Sentiment: CVS launched a nationwide bandage-art contest. The marketing initiative reinforces consumer engagement but is not expected to significantly influence near-term financial results. CVS Launches Wear Your HeART Bandage Art Contest
• Negative Sentiment: Proposed Medicare restrictions on remote patient monitoring could reduce reimbursement or utilization for CVS and raise uncertainty about the business’s outlook. CVS, UnitedHealth and Kaiser are pushing back, but investors may remain cautious until Medicare clarifies the final rules. UnitedHealth, CVS Push Back on Medicare Remote Patient Monitoring Plan

About CVS Health

CVS Health Corporation is an American health care company headquartered in Woonsocket, Rhode Island. Founded in 1963 as Consumer Value Stores, the company has expanded from a chain of retail pharmacies into an integrated health care organization serving consumers, employers, health plans, government programs and health care providers.

CVS Health operates through several major businesses. Its Health Care Benefits segment, anchored by Aetna, provides health insurance products and related services for employers, individuals, Medicare and Medicaid members.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.